[
  {
    "ts": "2025-12-01T13:18:00+00:00",
    "headline": "Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
    "summary": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demonstrated rapid and substantial reduction in immunoglobulin G levels, one of the root causes of gMG gMG patients taking nipocalimab demonstrated up to 20 months of sustained disease control and symptom relief in the Vivacity-MG3 study and ongoi",
    "url": "https://finance.yahoo.com/news/johnson-johnson-receives-european-commission-131800372.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9b1cc7ab-1d04-391a-bf52-c2ec9ae3d594",
      "content": {
        "id": "9b1cc7ab-1d04-391a-bf52-c2ec9ae3d594",
        "contentType": "STORY",
        "title": "Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
        "description": "",
        "summary": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demonstrated rapid and substantial reduction in immunoglobulin G levels, one of the root causes of gMG gMG patients taking nipocalimab demonstrated up to 20 months of sustained disease control and symptom relief in the Vivacity-MG3 study and ongoi",
        "pubDate": "2025-12-01T13:18:00Z",
        "displayTime": "2025-12-01T13:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3",
          "originalWidth": 2690,
          "originalHeight": 510,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFgHjEGtPkqKstjJ7xH84w--~B/aD01MTA7dz0yNjkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 2690,
              "height": 510,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m.9C60wTcxkvOQOLX1h8uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-receives-european-commission-131800372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-receives-european-commission-131800372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]